NAS:JNCE (USA)
Business Description
Jounce Therapeutics Inc
NAICS : 325412
SIC : 2834
780 Memorial Drive, Cambridge, MA, USA, 02139
Compare
Compare
Traded in other countries / regions
21J.Germany
•
JNCE.USA
Description
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.5 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -6.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -35.4 | |||||
| 3-Year EBITDA Growth Rate | -28 | |||||
| 3-Year EPS without NRI Growth Rate | -29.4 | |||||
| 3-Year FCF Growth Rate | 5.6 | |||||
| 3-Year Book Growth Rate | 11.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 93.23 | |||||
| 9-Day RSI | 85.04 | |||||
| 14-Day RSI | 76.67 | |||||
| 6-1 Month Momentum % | -58.58 | |||||
| 12-1 Month Momentum % | -33.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.78 | |||||
| Quick Ratio | 6.78 | |||||
| Cash Ratio | 6.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -59.62 | |||||
| ROA % | -52.79 | |||||
| ROIC % | -213.24 | |||||
| ROC (Joel Greenblatt) % | -602.9 | |||||
| ROCE % | -57.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.72 | |||||
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | -1.12 | |||||
| EV-to-EBITDA | -1.14 | |||||
| EV-to-Revenue | 4.41 | |||||
| EV-to-Forward-Revenue | 1.99 | |||||
| EV-to-FCF | -1.21 | |||||
| Price-to-Net-Current-Asset-Value | 1.98 | |||||
| Price-to-Net-Cash | 2.12 | |||||
| Earnings Yield (Greenblatt) % | -91.05 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:JNCE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.55 | ||
| Beta | 0.35 | ||
| Volatility % | 59.85 | ||
| 14-Day RSI | 76.67 | ||
| 14-Day ATR ($) | 0.308862 | ||
| 20-Day SMA ($) | 3.46 | ||
| 12-1 Month Momentum % | -33.96 | ||
| 52-Week Range ($) | 2.76 - 9.81 | ||
| Shares Outstanding (Mil) | 51.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jounce Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||